Last reviewed · How we verify
Vorinostat (VOR)
Vorinostat (VOR) is a Histone deacetylase (HDAC) inhibitor Small molecule drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved for Cutaneous T-cell lymphoma (mycosis fungoides), Peripheral T-cell lymphoma. Also known as: Zolinza.
Vorinostat inhibits histone deacetylases (HDACs), leading to accumulation of acetylated histones and altered gene expression that promotes cancer cell death.
Vorinostat is a small molecule histone deacetylase 1 inhibitor, classified as an INHIBITOR. It has been studied in clinical trials for conditions including HIV-1 Infection, HIV, and Colorectal Cancer.
At a glance
| Generic name | Vorinostat (VOR) |
|---|---|
| Also known as | Zolinza |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Histone deacetylase (HDAC) inhibitor |
| Target | Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
By blocking HDAC enzymes, vorinostat increases histone acetylation, which opens chromatin structure and allows transcription of genes involved in cell cycle arrest and apoptosis. This epigenetic mechanism is particularly effective in certain hematologic malignancies where HDAC inhibition triggers differentiation and death of cancer cells. The drug also induces reactive oxygen species and disrupts protein chaperone function.
Approved indications
- Cutaneous T-cell lymphoma (mycosis fungoides)
- Peripheral T-cell lymphoma
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Anorexia
- Thrombocytopenia
- QT prolongation
Key clinical trials
- The DART DELIVER-02 Study (PHASE1)
- Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer (PHASE2)
- Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART) (PHASE1)
- Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons (PHASE1)
- Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (PHASE1)
- The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vorinostat (VOR) CI brief — competitive landscape report
- Vorinostat (VOR) updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI
Frequently asked questions about Vorinostat (VOR)
What is Vorinostat (VOR)?
How does Vorinostat (VOR) work?
What is Vorinostat (VOR) used for?
Who makes Vorinostat (VOR)?
Is Vorinostat (VOR) also known as anything else?
What drug class is Vorinostat (VOR) in?
What development phase is Vorinostat (VOR) in?
What are the side effects of Vorinostat (VOR)?
What does Vorinostat (VOR) target?
Related
- Drug class: All Histone deacetylase (HDAC) inhibitor drugs
- Target: All drugs targeting Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8)
- Manufacturer: University of North Carolina, Chapel Hill — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cutaneous T-cell lymphoma (mycosis fungoides)
- Indication: Drugs for Peripheral T-cell lymphoma
- Also known as: Zolinza
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing